These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1857219)

  • 1. Assessment of biological activity of synthetic fragments of transforming growth factor alpha.
    Schultz G; Twardzik D
    Methods Enzymol; 1991; 198():200-13. PubMed ID: 1857219
    [No Abstract]   [Full Text] [Related]  

  • 2. Contribution of the transforming growth factor alpha B-loop beta-sheet to binding and activation of the epidermal growth factor receptor.
    Richter A; Drummond DR; MacGarvie J; Puddicombe SM; Chamberlin SG; Davies DE
    J Biol Chem; 1995 Jan; 270(4):1612-6. PubMed ID: 7829492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition by vaccinia virus growth factor.
    Lin YZ; Ke XH; Tam JP
    J Biol Chem; 1990 Nov; 265(31):18884-90. PubMed ID: 2229050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.
    Moriai T; Kobrin MS; Hope C; Speck L; Korc M
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):10217-21. PubMed ID: 7937865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A scintillation proximity assay for transforming growth factor alpha (TGF alpha).
    Hoffman R; Cameron L
    Biochem Soc Trans; 1991 Apr; 19(2):238S. PubMed ID: 1889604
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of receptor proteins for type-alpha transforming growth factor.
    Massagué J
    Methods Enzymol; 1987; 146():143-53. PubMed ID: 3316932
    [No Abstract]   [Full Text] [Related]  

  • 7. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
    Modjtahedi H; Dean C
    Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and characterization of a novel growth factor from human breast cancer cells.
    Lupu R; Wellstein A; Sheridan J; Ennis BW; Zugmaier G; Katz D; Lippman ME; Dickson RB
    Biochemistry; 1992 Aug; 31(32):7330-40. PubMed ID: 1324710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of erbstatin as protein-tyrosine kinase inhibitor.
    Umezawa K; Imoto M
    Methods Enzymol; 1991; 201():379-85. PubMed ID: 1658555
    [No Abstract]   [Full Text] [Related]  

  • 10. Constrained peptide analogues of transforming growth factor-alpha residues cysteine 21-32 are mitogenically active. Use of proline mimetics to enhance biological potency.
    Chamberlin SG; Sargood KJ; Richter A; Mellor JM; Anderson DW; Richards NG; Turner DL; Sharma RP; Alexander P; Davies DE
    J Biol Chem; 1995 Sep; 270(36):21062-7. PubMed ID: 7673134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity study of myxoma virus growth factor.
    Lin YZ; Ke XH; Tam JP
    Biochemistry; 1991 Apr; 30(13):3310-4. PubMed ID: 2009268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinase associated with chromatin that can be activated by ligand-p185c-Neu or epidermal growth factor-receptor interactions.
    Samanta A; Greene MI
    Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6582-6. PubMed ID: 7604037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The physiology of transforming growth factor-alpha.
    Derynck R
    Adv Cancer Res; 1992; 58():27-52. PubMed ID: 1546559
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis and biological activity of N-terminal-truncated derivatives of human epidermal growth factor (h-EGF).
    Shin SY; Shimizu M; Ohtaki T; Munekata E
    Peptides; 1995; 16(2):205-10. PubMed ID: 7784250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.
    Humphrey PA; Gangarosa LM; Wong AJ; Archer GE; Lund-Johansen M; Bjerkvig R; Laerum OD; Friedman HS; Bigner DD
    Biochem Biophys Res Commun; 1991 Aug; 178(3):1413-20. PubMed ID: 1678600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells.
    Rabiasz GJ; Langdon SP; Bartlett JM; Crew AJ; Miller EP; Scott WN; Smyth JF; Miller WR
    Br J Cancer; 1992 Aug; 66(2):254-9. PubMed ID: 1503897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betacellulin: a mitogen from pancreatic beta cell tumors.
    Shing Y; Christofori G; Hanahan D; Ono Y; Sasada R; Igarashi K; Folkman J
    Science; 1993 Mar; 259(5101):1604-7. PubMed ID: 8456283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of biologically active transforming growth factor alpha.
    Tam JP
    Int J Pept Protein Res; 1987 Mar; 29(3):421-31. PubMed ID: 3474216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1.
    Zhou L; Leung BS
    Biochim Biophys Acta; 1992 Dec; 1180(2):130-6. PubMed ID: 1463764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.